How our robotic isolator technology is setting a new standard for aseptic fill-finish
In the world of pharmaceutical manufacturing, our robotic isolator technology sets a new standard for aseptic fill-finish technology. By integrating...
Dr. Dave Seaward : 20 January 2022
PDF File: Cell and Gene Therapy: Converting a Rolls-Royce into a Ford?
With promising applications in the personalised medicines field, Cell and Gene Therapies are becoming more and more relevant. This, alongside 3Ps experience in the manufacturing of said therapies, has inspired 3P Founder and Projects Director Dave Seaward, to write a new blog series all about ATMPs!
Click the pdf link above and take a read of the first blog in the series.
This first blog focuses around the manufacture of cell and gene therapies with an interesting analogy to the automotive industry. It also looks at how 3P innovation can help with the manufacture of these life-changing ATMPs.
In the world of pharmaceutical manufacturing, our robotic isolator technology sets a new standard for aseptic fill-finish technology. By integrating...
Demand for the design and development of specialist aseptic manufacturing solutions is being driven by the significant growth in biological drug...
Over the next few years, a wave of patent expirations for leading inhaled therapies will fundamentally change the Dry Powder Inhaler (DPI) market....